Ryan Butts

Survival comparison for renal replacement therapy in pediatric VAD patients versus those not on therapy, over one year.

Outcomes of ventricular assist device placement in pediatric patients with renal dysfunction requiring dialysis: an ACTION registry analysis

Children who needed renal replacement therapy at the time of VAD implantation were rare, sicker, and had lower one-year survival than other VAD patients. But after accounting for other factors, the therapy itself was not independently linked to mortality.

Outcomes of ventricular assist device placement in pediatric patients with renal dysfunction requiring dialysis: an ACTION registry analysis Read More »

RVAD timing in pediatric BiVAD support

Does Earlier Right Ventricular Assist Device Implant Confer a Survival Advantage

Concerns about survival have made biventricular support less common in children. Drawing on 223 pediatric patients in the ACTION registry, this study asked whether the timing of RVAD placement matters. Patients who received both devices in a single operation had better one-year survival, despite being sicker going into surgery.

Does Earlier Right Ventricular Assist Device Implant Confer a Survival Advantage Read More »

Explantation Of Durable Ventricular Assist Device For Myocardial Functional Recovery In Children: A Report From The ACTION Registry

A multi-center ACTION registry study found that while VAD removal following heart recovery is rare in children (about 3%), nearly three-quarters of those who underwent explantation remained alive without needing a transplant or new device at two-year follow-up.

Explantation Of Durable Ventricular Assist Device For Myocardial Functional Recovery In Children: A Report From The ACTION Registry Read More »

The Pulse - January 2024

The Pulse — January 2024

Happy New Year! We hope you enjoyed the Holiday Season and are energized for a new year! We wrapped 2023 with the launch of several exciting projects, such as the HeartMate 3TM Discharge Bundle and Heart Healthy Video Series, we continued access to the Berlin Heart Active Driver under the extended trial, and we published new ACTION research. Looking ahead this year we have been meeting individually with all ACTION sites to ensure successful engagement in ACTION and highlight membership benefits for each center. We are excited to expand quality improvement, education, research, and best practice initiatives across the network, as well as engage with Global centers and increase advocacy efforts in the pediatric heart failure space. Reach out with any new ideas for the year ahead. Thank you for your continued efforts!

The Pulse — January 2024 Read More »